Intrinsiqq
Oruka Therapeutics, Inc. logo

Oruka Therapeutics, Inc.

ORKA

Compare

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$7.27B
EPS-$2.34
P/E-45.83
P/FCF-58.68
EV/EBITDA-34.69
FCF Yield–
Div. Yield–
Net Debt/FCF7.4x
Oruka Therapeutics, Inc. intrinsic value
52-Week Range
$26.38$113.08

Profitability & Returns

Revenue

N/A

Net Income (TTM)

-$153M

Op. Margin

–

ROIC

-17.64%

Cash Flow & Balance Sheet

FCF (TTM)

-$124M

Op. Cash Flow (TTM)

-$124M

Net Debt

-$917M

Net Cash Position

Cash & Equiv.

$920M

Continue Research

Peers

Pharmaceutical Preparations · Pick stocks to compare with ORKA

CompareIntrinsic value
RANIRani Therapeutics Holdings Inc.
$0.57+1.43%10
AVIRAtea Pharmaceuticals Inc.
$4.22+0.48%40
IBOImpact Biomedical Inc.
$4.30-6.93%35
HROWHarrow Inc.
$29.37-3.26%15
SIGASiga Technologies Inc.
$3.14+0.32%24
XENEXenon Pharmaceuticals Inc.
$42.10+1.72%10
PRAXPraxis Precision Medicines Inc.
$346.21+2.55%10
CATXPerspective Therapeutics Inc.
$0.83+4.46%10

Held by ETFs

ORKA is in 63 US ETFs. The largest of them, with ORKA's weight in each:

Oruka Therapeutics (ORKA) in three numbers

Quality score
10/100
Best check: net debt, -$917M. Weakest: return on capital, -17.6%.
Quality
Dividend
None
No dividend in the SEC filings we hold.
Dividends
P/E
-45.83
Negative: a loss over the last twelve months. Price to free cash flow -58.68.
Financials

Questions about Oruka Therapeutics

Is Oruka Therapeutics a high-quality business?

Oruka Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from SEC filings. Its best check is net debt at -$917M, and its weakest is return on capital at -17.6%. The Quality tab shows every check against its target.

Does Oruka Therapeutics (ORKA) pay a dividend?

No. Oruka Therapeutics (ORKA) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 31 Oct 2026 (period ending 30 Sept 2026), SEC. Price: last close 11 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in ORKA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing ORKA

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.